This retrospective study aims to assess the efficacy, safety, and tolerability of sequential ADCs with similar cytotoxic mechanisms (SG and T-DXd) in the HER2-negative metastatic breast cancer setting and determine if the efficacy of sequential conventional cytotoxic chemotherapy may be impacted by ADC use. Here, ERBB2 is linked to breast cancer.